9 research outputs found
Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review
The relationship between inflammation and venous thrombosis is not well understood. An inflammatory response may be both the cause and consequence of venous thromboembolism (VTE). In fact, several risk factors of VTE modulate thrombosis through inflammatory markers. Acute pulmonary embolism (PE) is burdened by a remarkable mortality rate, up to 34% in severely ill patients presenting with hemodynamic instability. Initial mortality risk stratification is based on hemodynamic instability. Patients with a situation of hemodynamic stability require immediate further risk assessment based on clinical, imaging, and circulating biomarkers, as well as the presence of comorbidities. Some inflammatory biomarkers have shown potential usefulness in the risk stratification of patients with VTE, especially acute PE. C-reactive protein on admission is associated with 30-day mortality and bleeding in VTE patients. P-selectin is associated with right ventricle dysfunction in PE patients and might be associated with VTE recurrences and the extension of thrombosis. Tissue factor microparticles are associated with VTE recurrence in cancer-associated thrombosis. Other inflammatory biomarkers present scarce evidence (inflammatory cytokines, erythrocyte sedimentation rate, fibrinogen, leukocyte count). In this manuscript, we will review the prognostic role of different inflammatory biomarkers available both for clinical practice and research in VTE patients
Mid-Regional Pro-Adrenomedullin, Methemoglobin and Carboxyhemoglobin as Prognosis Biomarkers in Critically Ill Patients with COVID-19: An Observational Prospective Study
Depto. de MedicinaFac. de MedicinaTRUEpu
Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality
Evaluación del profesorado de Medicina en Práctica Clínica
Fac. de MedicinaFALSEsubmitte
Impact of conducting a genetic study on the management of familial hypercholesterolemia
[Background] Clinically diagnosed familial hypercholesterolemia (FH) may require a genetic test (GT) to confirm diagnosis. GT availability/accessibility is resource-dependent and usually restricted to specialized clinics. While GT has a diagnostic value, it has not yet defined its impact on long-term management and prognosis of FH.[Objective] The aim was to identify the clinical characteristics associated with the request for a GT in suspected heterozygous FH.[Methods] Retrospective study including adult patients with clinically suspected to be FH. Positive GT (GT+) was defined as having a pathogenic/likely pathogenic variant. Patients were stratified based on whether they had a genetic study conducted, and among those with a genetic study, according to those who did or did not have a GT+.[Results] From 4854 patients included, 3090 were performed a GT (GT+: 2113). Median follow-up: 6.2 years. A younger age, FH-related physical signs, premature coronary disease, higher low-density lipoprotein cholesterol (LDLc) and lower body mass index and triglycerides, associated higher odds of being conducted a genetic study. These patients had higher baseline LDLc (252 mg/dL vs. 211 mg/dL among clinically diagnosed patients) and experienced larger reductions over the follow-up (157.7 mg/dL vs. 113.5 mg/dL, respectively). A similar pattern was observed among patients with GT+ (vs. negative GT). LDLc target attainment was low but increased to 66–95% when a triple combination with statin/ezetimibe/proprotein convertase subtilisin kexin type 9-inhibitor was used. Cardiovascular events occurred in 3.2% and 3.1% of patients who conducted/not conducted a genetic study. Patients conducted a genetic analysis and those with GT+ tended to present the events earlier.[Conclusions] Genetic study, vs. having a clinical-only diagnosis, impacts the management of FH. Cardiovascular prognosis was similar in both groups, perhaps as a result of the more intensive management of patients with a genetic study.We want to particularly acknowledge the patients and the Biobank of the Aragon Health System (PT17/0015/0039) integrated in the Spanish National Biobanks Network for their collaboration. AJV-V acknowledges support from the Program “Beatriz Galindo” from the Ministry of Universities, Spain, and University of Seville, Spain.Peer reviewe
Compliance and Utility of a Smartphone App for the Detection of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease: Cohort Study
Background:
In recent years, mobile health (mHealth)-related apps have been developed to help manage chronic diseases. Apps may allow patients with a chronic disease characterized by exacerbations, such as chronic obstructive pulmonary disease (COPD), to track and even suspect disease exacerbations, thereby facilitating self-management and prompt intervention. Nevertheless, there is insufficient evidence regarding patient compliance in the daily use of mHealth apps for chronic disease monitoring.
Objective:
This study aimed to provide further evidence in support of prospectively recording daily symptoms as a useful strategy to detect COPD exacerbations through the smartphone app, Prevexair. It also aimed to analyze daily compliance and the frequency and characteristics of acute exacerbations of COPD recorded using Prevexair.
Methods:
This is a multicenter cohort study with prospective case recruitment including 116 patients with COPD who had a documented history of frequent exacerbations and were monitored over the course of 6 months. At recruitment, the Prevexair app was installed on their smartphones, and patients were instructed on how to use the app. The information recorded in the app included symptom changes, use of medication, and use of health care resources. The patients received messages on healthy lifestyle behaviors and a record of their cumulative symptoms in the app. There was no regular contact with the research team and no mentoring process. An exacerbation was considered reported if medical attention was sought and considered unreported if it was not reported to a health care professional.
Results:
Overall, compliance with daily records in the app was 66.6% (120/180), with a duration compliance of 78.8%, which was similar across disease severity, age, and comorbidity variables. However, patients who were active smokers, with greater dyspnea and a diagnosis of depression and obesity had lower compliance (P<.05). During the study, the patients experienced a total of 262 exacerbations according to daily records in the app, 99 (37.8%) of which were reported exacerbations and 163 (62.2%) were unreported exacerbations. None of the subject-related variables were found to be significantly associated with reporting. The duration of the event and number of symptoms present during the first day were strongly associated with reporting. Despite substantial variations in the COPD Assessment Test (CAT), there was improvement only among patients with no exacerbation and those with reported exacerbations. Nevertheless, CAT scores deteriorated among patients with unreported exacerbations.
Conclusions:
The daily use of the Prevexair app is feasible and acceptable for patients with COPD who are motivated in their self-care because of frequent exacerbations of their disease. Monitoring through the Prevexair app showed great potential for the implementation of self-care plans and offered a better diagnosis of their chronic condition.Depto. de MedicinaFac. de MedicinaTRUEpu
Adaptación de las prácticas de la asignatura Alimentación y Nutrición Pediátrica al espacio virtual
Este Proyecto de Innovación se ha elaborado para generar productos de innovación docente relacionados con la
virtualización de una asignatura, como consecuencia de:
1.-Adaptar los contenidos existentes relativos a la docencia práctica y crear contenidos nuevos para un entorno virtual.
2.-Crear nuevas presentaciones Power Point de los seminarios que se imparten en la asignatura, locutándolos y
añadiendo vídeo, para su manejo virtual.
3.-Crear un sistema de docencia práctica de casos clínicos adaptado a un entorno virtual.
4.- Realización de trabajos individuales: el alumno elegirá un tema relacionado con la docencia que se imparte, que le
resulte interesante y que le estimule para desarrollar un trabajo que le permita profundizar en el conocimiento del
mismo. Podrá usar tanto el material que él considere oportuno como los recursos bibliográficos o de otro tipo que le
recomiende el profesor. El profesor estará, a disposición del alumno para todo aquello que éste pudiera necesitar, y
cualquier duda que pudiera surgir en torno al tema elegido.
5.- Tutorías personalizadas: el alumno podrá plantear sus dudas al profesor comunicándose con él a través del
Campus Virtual. Así existirá una interacción entre profesor y alumno cuyo resultado será resolver cuantas dudas surjan
al alumno por un lado y por otro evaluar los progresos prácticos del alumno.
6.-Crear un sistema de autoevaluación aplicable a través del Campus Virtual, de manera que los alumnos puedan ir
de forma continúa comprobando cómo evolucionan sus conocimiento sobre la asignatura.
7.-Crear una base de preguntas y un sistema de calificación a través del Campus Virtual
Guía Europea de Prevención Cardiovascular en la Práctica Clínica: adaptación Española del CEIPC 2008
Presentamos la adaptación española realizada por el
CEIPC de la Guía Europea de Prevención de las Enfermedades
Cardiovasculares (ECV) 2008. Esta guía recomienda el
modelo SCORE de bajo riesgo para la valoración del riesgo
cardiovascular. El objetivo es prevenir la mortalidad y morbilidad
debidas a las ECV mediante el manejo de sus factores
de riesgo en la práctica clínica. La guía hace énfasis en
la prevención primaria y en el papel del médico y la enfermería
de atención primaria en la promoción de un estilo de
vida cardiosaludable, basado el incremento de los niveles de
actividad física, la adopción de una alimentación saludable
y, en los fumadores, el abandono del tabaco. La meta terapéutica
para la presión arterial es en general <140/90
mmHg; pero en pacientes con diabetes, enfermedad renal
crónica o ECV el objetivo es 130/80 mmHg. El colesterol
debe mantenerse por debajo de 200 mg/dl (cLDL < 130
mg/dl); en los pacientes con ECV o diabetes el objetivo es
cLDL < 100 mg/dl (80 mg/dl si factible en sujetos de muy
alto riesgo). En diabetes tipo 2 y en pacientes con síndrome
metabólico se debe reducir el peso y aumentar la actividad
física y en su caso utilizar los fármacos indicados, para
alcanzar los objetivos de IMC y de perímetro de cintura. El
objetivo en diabéticos tipo 2 debe ser alcanzar una HbA1C
< 7%. La amplia difusión de las guías y el desarrollo de los
programas destinados a favorecer su implantación, identificando
barreras y buscando soluciones, son objetivos prioritarios
del CEIPC, como uno de los medios fundamentales
para trasladar las recomendaciones establecidas a la práctica
clínica diaria